|Bid||2.5100 x 1800|
|Ask||2.5800 x 3100|
|Day's Range||2.3800 - 2.5900|
|52 Week Range||1.2300 - 5.2400|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 sales of $16.02 million. Earnings fell to a loss of $17.39 million, resulting in a 182.71% decrease from last quarter. In Q1, Rigel Pharmaceuticals earned $21.03 million, and total sales reached $55.76 million.What Is ROCE? Changes in earnings and sales indicate shifts in Rigel Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Rigel Pharmaceuticals posted an ROCE of -0.28%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on RIGLROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Rigel Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.In Rigel Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Recap Rigel Pharmaceuticals reported Q2 earnings per share at $-0.10/share, which beat analyst predictions of $-0.13/share.See more from Benzinga * Earnings Scheduled For August 4, 2020 * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session * Morning Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
It is now my pleasure to introduce our first speaker Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel. As a reminder, during today's call we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. At this time, I would like to turn the call over to our CEO, Raul Rodriguez.
Rigel (RIGL) delivered earnings and revenue surprises of 23.08% and 12.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?